Gastric cancer is a common solid tumor of digestive system.Among the high incidence cancers in China, the incidence rate of gastric cancer is second only to that of lung cancer, ranking the second among all malignant tumors, 400000 to 500000 new cases occur every year. In China, once gastric cancer is clinically diagnosed, it is usually in the middle and advanced stage.
Vice president of Peking University Cancer HospitalShen LinAnd collaborators found that,Cellular immunotherapy specifically targeting chimeric antigen receptor T cells (car-t), a protein highly expressed in gastrointestinal tumors (cldn18.2), is safe, the remission rate was 48.6%in patients with gastrointestinal cancer and 57.1%in patients with gastric cancer. These findings suggest that cldn18 2 specific car-t cell therapy or a feasible treatment for patients with digestive system cancer. The relevant research was published in nature medicine on May 9.
Car-t cell therapy (an immunotherapy that modifies patients’t cells to recognize and kill cancer cells) has been approved for the treatment of blood cancers such as leukemia and lymphoma. However, the potential of car-t in the treatment of parenchymal tumors, such as gastrointestinal cancer, is unclear because it is difficult to target these types of cancers.
Shen Lin和同事提出了一项进行中的1期临床试验的初步分析，该试验在过去经过治疗的表达CLDN18.2的胃肠道癌症患者（共37名患者，28名患有胃癌或食管胃结合部腺癌，5名患有胰腺癌）中，研究靶向CLDN18.2的CAR-T细胞。Overall, the safety observed after the first infusion of car-t cells was acceptable. The total remission rate and disease control rate in all patients were 48.6%and 73.0%, respectively, and 57.1%and 75.0%in patients with gastric cancer.
The authors said that these results provide new insights into the application of car-t cells in the treatment of solid tumors,However, the test is still in progress and needs to wait for the final results and subsequent larger-scale tests.
Relevant paper information: